NZ741667A - Prostate-associated antigens and vaccine-based immunotherapy regimens - Google Patents
Prostate-associated antigens and vaccine-based immunotherapy regimensInfo
- Publication number
- NZ741667A NZ741667A NZ74166713A NZ74166713A NZ741667A NZ 741667 A NZ741667 A NZ 741667A NZ 74166713 A NZ74166713 A NZ 74166713A NZ 74166713 A NZ74166713 A NZ 74166713A NZ 741667 A NZ741667 A NZ 741667A
- Authority
- NZ
- New Zealand
- Prior art keywords
- vaccine
- immunogenic
- antigen
- nucleic acid
- polypeptides
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. The claimed invention relates to dual-antigen constructs encoding two of PSA, PSCA, and PSMA, characterised by the PSA antigen being an immunogenic cytosolic PSA antigen sequence and/or the PSMA antigen being an immunogenic truncated membrane bound PSMA antigen sequence.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642844P | 2012-05-04 | 2012-05-04 | |
NZ71949913 | 2013-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ741667A true NZ741667A (en) | 2019-11-29 |
Family
ID=68652888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ74174213A NZ741742A (en) | 2012-05-04 | 2013-04-29 | Prostate-associated antigens and vaccine-based immunotherapy regimens |
NZ74166713A NZ741667A (en) | 2012-05-04 | 2013-04-29 | Prostate-associated antigens and vaccine-based immunotherapy regimens |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ74174213A NZ741742A (en) | 2012-05-04 | 2013-04-29 | Prostate-associated antigens and vaccine-based immunotherapy regimens |
Country Status (1)
Country | Link |
---|---|
NZ (2) | NZ741742A (en) |
-
2013
- 2013-04-29 NZ NZ74174213A patent/NZ741742A/en not_active IP Right Cessation
- 2013-04-29 NZ NZ74166713A patent/NZ741667A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ741742A (en) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502438A1 (en) | Prostate-associated antigens and vaccine-based immunotherapy regimens | |
CY1121934T1 (en) | ANTI-FCRN ANTIBODIES | |
CA2817709C (en) | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | |
CY1125392T1 (en) | COMPOSITIONS AND METHODS OF PROTEINS | |
MX2015008446A (en) | Multivalent binding protein compositions. | |
BR112013005699A2 (en) | 4-1bb binding molecules | |
MX2019007921A (en) | Novel ha binding agents. | |
DK2681244T3 (en) | CEA ANTIBODIES | |
MX352974B (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof. | |
MX2018008135A (en) | Influenza nucleic acid molecules and vaccines made therefrom. | |
MX2013007904A (en) | Anti-il-12/il-23 antibodies and uses thereof. | |
EA201990114A1 (en) | PR13.5 PROMOTOR FOR SUSTAINABLE T-CELL AND HUMORAL IMMUNE REACTIONS | |
EA201300896A1 (en) | MUTANT POLYPEPTIDES OF INTERLEUKIN-2 | |
WO2012018907A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
BR112018073660A2 (en) | anti-factor ix padua antibodies | |
WO2013138259A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
PH12018501532A1 (en) | Cancer vaccines | |
NZ741667A (en) | Prostate-associated antigens and vaccine-based immunotherapy regimens | |
WO2013093514A3 (en) | Vaccines - peptides | |
WO2012076157A3 (en) | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2021 BY AJ PARK Effective date: 20200327 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2022 BY THOMSON REUTERS Effective date: 20210313 |
|
LAPS | Patent lapsed |